Journal of Clinical Investigation: A Conversation with Paul Marks by Ushma Neil

Paul Marks is recognized as a leader in the cancer field and as a world-class scientist, clinician, and administrator. He served as president and CEO of Memorial Sloan-Kettering Cancer Center (MSKCC) between 1980 and 1999 after serving as the dean (1970–1973) and vice president for Medical Sciences (1973–1980) of the Columbia University College of Physicians and Surgeons (P&S).

Marks led the discovery, testing, and recent approval of SAHA (suberoylanilide hydroxamic acid), the treatment for cutaneous T-cell lymphoma. SAHA and other histone deacetylase (HDAC) inhibitors are now undergoing trials for a broad array of cancers.

The Journal of Clinical Investigation is a top-tier venue for critical advances in biomedical research. The JCI has a 2011 Impact Factor of 13.069 and a 5-year Impact Factor of 15.430, placing it second in the category of Medicine, Research and Experimental. This along with free access to all of its research articles makes the JCI a prestigious, high-impact venue for authors seeking the broadest audience for their most important work.

The journal is headed by Editor in Chief Dr. Howard Rockman and an Editorial Board of peer scientists at Duke University Medical Center, the University of North Carolina, Duke-NUS, and Sanford-Burnham Medical Research Institute whose depth and experience ensure fair and competent peer review.

Ushma S. Neill obtained her Ph.D. in biomedical engineering from Northwestern University studying pulmonary mechanics and used her Marshall Sherfield Postdoctoral Fellowship at Imperial College, London, to study vascular permeability. After 2 years as an editor at Nature Medicine, she joined the JCI in March 2003 as Executive Editor. In May 2012, Ushma became Director of the Office of the President of Memorial Sloan-Kettering Cancer Center.